Bortezomib in combination with dexamethasone and subsequent thalidomide for newly-diagnosed multiple myeloma: A Chinese experience

Leukemia Research

Volumn 33, Issue 12, 2009, Pages 1615-1618

  Zheng, Weiyan ^a   Wei, Guoqing ^a   Ye, Xiujin ^a   He, Jingsong ^a   Li, Li ^a   Wu, Wenjun ^a   Shi, Jimin ^a   Zhang, Jie ^a   Huang, Weijia ^a   Xie, Wanzhuo ^a   Luo, Yi ^a   Xue, Xingkui ^a   Lin, Maofang ^a   Huang, He ^a   Cai, Zhen ^a  

^a ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Bortezomib; Dexamethasone; Multiple myeloma; Thalidomide

Indexed keywords

BORTEZOMIB; DEXAMETHASONE; THALIDOMIDE;

ADULT; AGED; ARTICLE; CHINESE; CLINICAL ARTICLE; DEEP VEIN THROMBOSIS; DIARRHEA; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; FATIGUE; FEMALE; HERPES ZOSTER; HUMAN; LUNG EMBOLISM; MALE; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; NAUSEA; NEUROPATHY; ORTHOSTATIC HYPOTENSION; OUTCOME ASSESSMENT; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; THROMBOCYTOPENIA;

ANTINEOPLASTIC AGENTS; BORONIC ACIDS; DEXAMETHASONE; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; PYRAZINES; THALIDOMIDE;

EID: 70349190077     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2009.04.006     Document Type: Article

References (24)

1. Child J.A., Morgan G.J., Davies F.E., et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med 348 (2003) 1875-1883
2. Facon T., Mary J.Y., Pegourie B., et al. Dexamethasone-based regimens versus melphalan-prednisone for elderly multiple myeloma patients ineligible for high-dose therapy. Blood 107 (2006) 1292-1298
3. Palumbo A., Bringhen S., Caravita T., et al. Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial. Lancet 367 (2006) 825-831
4. Singhal S., Mehta J., Desikan R., et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 341 (1999) 1565-1571
5. Ma M.H., Yang H.H., Parker K., et al. The proteasome inhibitor PS-341 markedly enhances sensitivity of multiple myeloma tumor cells to chemotherapeuticagents. Clin Cancer Res 9 (2003) 1136-1144
6. Anagnostopoulos A., Weber D., Rankin K., et al. Thalidomide and dexamethasone for resistant multiplemyeloma. Br J Haematol 121 (2003) 768-771
7. Richardson P.G., Barlogie B., Berenson J., et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 348 (2003) 2609-2617
8. Jagannath S., Barlogie B., Berenson J., et al. A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma. Br J Haematol 127 (2004) 165-172
9. Richardson P.G., Sonneveld P., Schuster M.W., et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 352 (2005) 2487-2498
10. Sagaster V., Ludwig H., Kaufmann H., et al. Bortezomib in relapsed multiple myeloma: response rates and duration of response are independent of a chromosome 13q-deletion. Leukemia 21 (2007) 164-168
11. Jagannath S., Richardson P.G., Barlogie B., et al. Bortezomib in combination with dexamethasone for the treatment of patients with relapsed and/or refractory multiple myeloma with less than optimal response to bortezomib alone. Haematologica 91 7 (2006) 929-934
12. Orlowski R.Z., Nagler A., Sonneveld P., et al. Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression. J Clin Oncol 25 25 (2007) 3892-3901
13. Yuan Z.G., Hou J., Zhou F., et al. Bortezomib in combination with dexamethasone for the treatment of relapsed or refractory multiple myeloma. Zhonghua Xue Ye Xue Za Zhi 27 10 (2006) 653-655
14. Wang M., Giralt S., Delasalle K., et al. Bortezomib in combination with thalidomide-dexamethasone for previously untreated multiple myeloma. Hematology 12 3 (2007) 235-239
15. Mateos M.V., Hernandez J.M., Hernandez M.T., et al. Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: results of a multicenter phase 1/2 study. Blood 108 7 (2006) 2165-2172
16. Greipp P.R., San Miguel J., Durie B.G., et al. International staging system for multiple myeloma. J Clin Oncol 23 (2005) 3412-3420
17. Bladé J., Samson D., Reece D., et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant. Br J Haematol 102 (1998) 1115-1123
18. National Cancer Institute Cancer Therapy Evaluation Program Common Toxicity Criteria version 2.0. http://ctep.cancer.gov/forms/ctcv2nom-4-30-99-final3.pdf.
19. Richardson P.G., Barlogie B., Berenson J., et al. Extended follow-up of a phase II trial in relapsed, refractory multiple myeloma: final time-to-event results from the SUMMIT trial. Cancer 106 6 (2006) 1316-1319
20. Richardson P.G., Sonneveld P., Schuster M., et al. Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial. Blood 110 10 (2007) 3557-3560
21. Berenson J.R., Yang H.H., Sadler K., et al. Phase I/II trial assessing bortezomib and melphalan combination therapy for the treatment of patients with relapsed or refractory multiple myeloma. J Clin Oncol 24 6 (2006) 937-944
22. Kropff M.H., Bisping G., Wenning D., et al. Bortezomib in combination with dexamethasone for relapsed multiple myeloma. Leuk Res 29 5 (2005) 587-590
23. Zangari M., Yaccoby S., Cavallo F., et al. Response to bortezomib and activation of osteoblasts in multiple myeloma. Clin Lymphoma Myeloma 7 (2006) 109-114
24. Terpos E., Sezer O., Croucher P., et al. Myeloma bone disease and proteasome inhibition therapies. Blood 110 (2007) 1098-1104